InvestorsObserver
×
News Home

Evogene Ltd Ord Up 2.73% To $0.65 After Earnings

Wednesday, November 15, 2023 12:10 PM | InvestorsObserver Analysts

Mentioned in this article

Evogene Ltd Ord Up 2.73% To $0.65 After Earnings

Evogene Ltd (EVGN) surpassed earnings projections on 11/15/2023 for Q3 2023.

reported that it broke-even during the quarter.



The stock is up 2.73% to $0.65 after the report.

Evogene Ltd Ord's profit margins maintained as both earnings and revenue declined at the same pace.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 54. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App